Akili Inc (AKLI) Stock

DelistedNasdaq: AKLIAkili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies.

0.43
Final close · Jul 1, 2024

AKLI is no longer traded. Akili was delisted from the Nasdaq in July 2024.

Prices on this page are historical; the last trade was July 1, 2024 at $0.43.

Akili stock price history

Split-adjusted closes, 2022–2024

AKLI final trading statistics

Final close
$0.43
Final trading day
Jul 1, 2024
Market cap at delisting
$34.01M
Shares outstanding
78.73M
Final 52-week range
$0.19 – $1.25
Avg. volume (final 3 mo.)
1,984,250
All-time high (split-adj.)
$14.07 · Aug 2022
All-time low (split-adj.)
$0.21 · Apr 2024
Return since IPO
-95.7%
Beta
1.73
Book value / share
$0.64
Price / book
0.68
Final 52 wk
0.191.25

Akili earnings per share

Earnings per share

Akili revenue & net income

RevenueNet income

Akili annual financials

Akili Inc revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2023$1.68M-$59.5M-$0.69
FY2022$323.0K-$8.0M-$0.46
FY2021$538.0K-$61.8M-$0.08
FY2020$3.94M-$25.6M—
FY2019$19.99M-$20.6M—

Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About Akili Inc

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. As of July 1, 2024, Akili, Inc. operates as a subsidiary of Virtual Therapeutics Corp.

Akili stock FAQ

What happened to Akili stock?

Akili stock was delisted from the Nasdaq. Its final close was $0.43 on July 1, 2024.

Is AKLI stock still trading?

No. AKLI was delisted from the Nasdaq in July 2024 and no longer trades on a U.S. exchange.

What was the last price of AKLI stock?

AKLI closed at $0.43 on its final trading day, July 1, 2024, for a market value of about $34.01M.

What were Akili's revenue and earnings in its last full fiscal year?

Akili reported revenue of $1.68M and net income of -$59.5M in fiscal 2023, its last full year as a public company.

When did Akili go public?

Akili Inc stock began trading on August 19, 2022.

Health Information Services stocks to research

All Healthcare stocks →